Day 1 | Monday

November 13, Monday

Inauguration Ceremony - @ Diamond Ballroom
Coffee Break & Reception - @ Foyer
Lunch - @ Syrah Restaurant
Poster Session - @ Room SIX

WiFi:
Connect to the network: Scientific
Enter Password: scientific

Exhibitors

United Scientific Group
Mucosys
GenScript
Desert King
Sanofi Pasteur

We are excited to use Whova as our event platform. Attendees please download Whova event app.

We wish to meet you again at Vaccines R&D-2018

Venue
Sheraton Reston Hotel
11810 Sunrise Valley Dr, Reston
VA 20191, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:30</td>
<td>Translation of cancer vaccines from mice to human clinical trials</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Vaccine design to safely induce protective immunity of long duration</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Uncoupling immunodominance, antigenic variation and strain-restricted immunity in developing the next generation of vaccines and monoclonal antibodies</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Stereo-electronic rules for chemically vaccines</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee Break &amp; Networking</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Free parasite biology to T cells to African infants to generate editing and edit toward biocure of the first and future generations of live parasite Plasmodium falciparum sporozoite vaccines</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Intradermal delivery of DNA vaccines: Getting more from less</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Lunch &amp; Networking</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Development of vaccines using Sendai virus vectors</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>HOOKVAC: A case study for vaccine development to fight neglected infectious diseases</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Challenges for registration of vaccines at global level</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Regulatory considerations for preventive vaccine development: A U.S. FDA perspective</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Coffee Break &amp; Networking</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Optimizing vaccine R&amp;D and registration in Africa: The role of the African Vaccine Regulatory Forum (AVAREF)</td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>Vaccine research and development in China Status of product development and regulatory land scope</td>
</tr>
<tr>
<td>17:30-18:00</td>
<td>Routine immunization in developing countries: Civil war and religious misconceptions briefs</td>
</tr>
</tbody>
</table>
Day - 2
November 14, Tuesday

We are excited to use Whova as our event platform. Attendees please download Whova event app.

Venue
Sheraton Reston Hotel
11810 Sunrise Valley Dr, Reston
VA 20191, USA

We wish to meet you again at
Vaccines R&D-2018
Symposium Title: The Long Road to an HIV Vaccine

13:05-14:00 Lunch & Networking @ Syrah Restaurant

14:00-14:25 Lysosomally-associated membrane protein-1 targeting of antigen for increased efficacy of DNA vaccinations
Patrick Jemmrich, Immunomic Therapeutics Inc., USA
14:25-14:50 A new source of neoantigens offers new approaches to personal and preventative cancer vaccines
Stephen Albert Johnson, Arizona State University, USA
14:50-15:15 A rapid platform assay for immunogenicity testing of cancer (neo)antigens amenable to predict responders from non-responders
Pallavi Duttaray, TBI, USA International
15:15-16:10 Coffee Break & Networking @ Ballroom Foyer

Session II: Chairs - Kenneth Miller & Ton Hoek

16:10-16:35 The road to a pediatric HIV vaccine
Karen Del Rio, UNC at Chapel Hill, USA
16:35-16:50 HIV Env antibody can provide sterile immunity in the strictest sense
Klaus Lell, University Hospital Dusseldorf, Dusseldorf, Germany
17:00-17:15 Mucosal vaccination with accessory antigens provides superbly robust protection against early HIV-1 replication. Undersupervised role of location and immunomodulation in vaccination against chronic infection?
Peter Johannes Holst, University of Copenhagen, Denmark
17:20-17:35 Stabilization of gp120 outer domain for HIV-1 vaccine design
Shinya Xiong, University of Nebraska-Lincoln, Nebraska Center for Virology, USA
17:45-18:00 Influenza H5N1 and H7N9 viruses that evade envelope CD4 reactivity
Paul Yu, Kansas State University, USA
18:00-20:00 Targeting tumor-associated carbohydrate antigens for cancer therapy
Thomas Pape, Emory University, Atlanta, USA
18:00-20:05 Nano-vaccine platform technology for personalized cancer vaccination
Jason J. Maguire, Johns Hopkins University, USA
18:05-20:15 Tunable lipidated protein as potential vaccine for lung cancer patients
Giulio Tarro, Fondazione Istituto di Ricerche Sanitari per l'Oncologia, Italy
20:15-20:30 Correlates of protection from mosquito to mosquito transmission: induced by the oral live-attenuated Shigella vaccine candidate CVD 103HIS in humans
Farshad Guirakhoo, GeoVax Labs, USA
20:30-20:45 Live attenuated chimeric- RVA virus candidate
Farshad Guirakhoo, GeoVax Labs, USA
20:45-20:55 Oral delivery of Sf2A-AgV1 neoantigen based on native Sf2A sequence eradicates murine cancer by promoting anti-cancer immunity
Ariel L. Rivas, University of New Mexico, USA
20:55-21:05 Novel universal nanoparticle vaccines for bird flu and coronavirus infections in birds
Rita Sunagar, Albany Medical College, USA
21:05-21:15 Vaccines elicited broadly neutralizing antibodies against New World hantaviruses, a few case reports
Jonathan Abraham, Harvard Medical School, USA
21:15-21:25 Cancers, vaccines & biologics
Chair: Collin Canes, Biologics Resources LLC, USA
21:25-21:45 Deconvolution of neutralizing antibody response induced by a tetravalent parainfluenza-vectored ebolavirus vaccine
Brian Finley, University of Texas Medical Branch, USA
21:45-21:55 Comparative analysis of the antibody threshold of protection for the licensed biobrew arenavirus vaccine and other novel arenavirus vaccine candidates
Marcelo B. Sztein, University of Maryland, USA
21:55-22:05 Live attenuated chimeric- RVA virus candidate
Farshad Guirakhoo, GeoVax Labs, USA
22:05-22:15 Formulation and delivery of biothrax anthrax vaccine and other novel anthrax vaccine candidates
Collin Canes, Biologics Resources LLC, USA
22:15-22:30 Development of the VesiculoVax™ vaccine platform to rapidly respond to new epidemic diseases
Jennifer A. Schwartz, Proteics Biosciences, Inc, USA
22:30-22:45 Development of the VaxProLux™ vaccine platform to rapidly respond to new epidemic diseases
Jennifer A. Schwartz, Proteics Biosciences, Inc, USA
22:45-22:55 Use of an outbred mouse model for Franciella tularensis vaccine development and testing
Rita Sunagar, Albany Medical College, USA
22:55-23:05 Vaccines elicited broadly neutralizing antibodies against New World hantaviruses, a few case reports
Jonathan Abraham, Harvard Medical School, USA

Session IIA: Chairs - Nathan Crumpton & Neil S. Greenspan

10:30-11:00 Coffee Break & Networking @ Ballroom Foyer

11:00-11:25 HIV Env trier immunogen design and modification to elicit neutralizing antibodies
Richard Wyatt, National Cancer Institute, USA
11:25-11:50 HIV/AIDS vaccine development: Defending the frontline
Ruth Reapsher, Texas Biomedical Research Institute, USA
11:50-12:15 Fundamental challenges to the development of an HIV vaccine
Alan H. Un, Texas A&M University School of Medical Health in Houston, USA
12:15-12:40 Host genetic variability and HIV vaccines: a focus on low affinity Fcγ receptors
Carole T. Tenner-Vogg, National Cancer Institute, USA
12:40-13:05 Orally delivered mucosal vaccine targeting colostral immunity protected SHIV transmission in macaques
Yongjun Sui, National Cancer Institute, USA
13:05-14:00 Lunch & Networking @ Syrah Restaurant

Session IIA: Chairs - Nathan Crumpton & Neil S. Greenspan

14:00-14:25 Efficacy of live attenuated vaccine to prevent abortion due to Neospora caninum in newborns
Sophia Vouros, Washington State University, USA
14:25-14:50 Riemerella anatipestifer mutant RA-M1 bio vectored parainfluenza-debolavirus vaccine
Christine E. Ferragine, Biologics Resources LLC, USA
14:50-15:15 Development of the VesiculoVax™ vaccine platform to rapidly respond to new epidemic diseases
Jennifer A. Schwartz, Proteics Biosciences, Inc, USA
15:15-15:30 Targeting tumor associated carbohydrate antigens for cancer therapy
Rita Sunagar, Albany Medical College, USA
15:30-15:45 Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicating preclinical mouse models of HPV+ genital and oral cancer
Stephanie Doria-Emmery, Anderson Cancer Center, USA
15:45-15:55 Changing the tumor microenvironment of PDAC by novel immune-chemotherapeutic approaches
Benon C. Selvanesan, Albert Einstein College of Medicine, USA
15:55-16:10 Adenovirus vector-based prime-boost vaccination heterologous routes induces cancovaccinogend! C11 T-cell responses against HPV16 oncoproteins
Nicolu Nicola, National Cancer Institute, USA
16:10-16:35 Great Apes Adenovirus novel neoantigens-based vaccine synergizes with immunomodulators in mouse models of cancer
Anna Morina D’Alise, Nouscom AG, Switzerland
16:35-16:50 Orally delivered mucosal vaccine targeting colostral immunity protected SHIV transmission in macaques
Yongjun Sui, National Cancer Institute, USA
16:50-17:05 Nano-vaccine platform technology for personalized cancer vaccination
Ariel L. Rivas, University of New Mexico, USA
17:05-17:20 A new source of neoantigens offers new approaches to personal and preventative cancer vaccines
Stephen Albert Johnson, Arizona State University, USA
17:20-17:35 A rapid platform assay for immunogenicity testing of cancer (neo)antigens amenable to predict responders from non-responders
Pallavi Duttaray, TBI, USA International
Session IV: 09:40 - 10:05

Session Title: The Long Road to an HIV Vaccine

Track - D | @ J. Ballroom 9610

Influenza Vaccines/Virus

Chair: Jay R. Banes, Johns Hopkins Bloomberg School of Public Health, USA

ACDC reporter biossay and vaccine development
Marc Con, Pongo.com; Corporation, USA
08:30-08:25

Stability improvements to subunit and live attenuated influenza vaccines
Leslie A. Walkow, PATH, USA
08:25-08:50

Heterospecific T cell responses to inactivated and live attenuated seasonal influenza vaccines
Jay B. Hennes, Hopkins Bloomberg School of Public Health, USA
08:50-09:15

Repeat annual seasonal influenza vaccines: The benefit of a changing vaccine formulation
Travis R. Perez, Center for Biological Evaluation and Research, USA
09:15-09:40

A split, inactivated influenza virus vaccine containing an engineered H5 hemagglutinin elicits broadly protective antibodies
Maysarah Al-Falouji, Sandor Palfy, USA
09:40-10:05

Track - E | @ Meeting Room 5

DNA Vaccines & Vaccines Against Respiratory Pathogens

Chair: Trudy G. Morton, University of Massachusetts Medical School, USA

Cytolytic DNA vaccine to induce antigen cross-presentation by dendritic cells to cause protective effects on human pulmonary sarcoma MDAMB-231 cells
Darshana Kumara Wewesatara, The University of Adelaide, Australia
08:00-08:25

ARC targeting of antigen for increased efficacy of DNA vaccination
Gwenn Grocock, University of Oslo, Norway
08:25-08:50

Resident humoral response elicited by repeatedly same site inoculation inhibits systemic immunity of gene-based vaccines
Yann Kim, University of Nebraska-Lincoln, USA
08:50-09:15

Reshaping mucosal immune response and immune responses using novel adjuvant DNA
Purnam Dubey, The Ohio State University, USA
09:15-09:40

The safety and immunogenicity of quadrivalent HPV (9/11) vaccine in systemic lupus erythematosus
J. Patricia, Doria, Wayne State University School of Medicine, USA
09:40-10:05

Lunch & Networking | @ Syrah Restaurant

12:35-13:00

3M’s hollow microneedle system and toll-like receptor 7/8 agonist 3M-052 for enhancing vaccine effectiveness
Mark Todd, 3M Drug Delivery Systems, USA
12:35-13:00

Imaging of general center immune dynamics: Applications in vaccine development
Corina Stefanescu-Vitvitska, Vaccine Research Center, NIAID, NIH, USA
14:00-14:20

Therapeutic vaccine against primate papillomavirus infections of the cervix
Laura Tran, Vaccine Research & Development Research, USA
14:25-14:50

Cell immune therapy of cancers using anti - gene anti IGF-I vaccine
Jermaine Tran, UVA, University, USA
15:15-15:40

BPZ11, a live attenuated herpesvirus vaccine Manufacturing challenges & solutions
Marcel Traxel, Bad Biosciences, Belgium
16:05-16:30

The role of positive influence of Venom Immunotherapy (VIT) on other allergies
Leonora Nienke Everts, Abagelhome immunology, Russia
16:40-16:50

13:00-14:00

Track - C | @ Meeting Room 5

New Vaccine Development

Chair: Edith Jasny, CureVac AG, Germany

Systematic evaluation of self-assembling and self-adjuvinating lipopeptide vaccine candidates for the induction of protective immune responses
Rachel Stephenson, The University of Queensland, Australia
11:20-11:45

Adjuvant-independent intranasal vaccination via human fcyR-targeted fusion protein (Edwards) Cossette, Monash Medical College, Australia
11:45-12:10

Antigen display and therapeutic potential of a buycout VLP-like nanoparticle
Shiladitya DasSarma, University of Maryland School of Medicine, USA
12:10-12:35

Age to end dreadful diseases (HIV, Malaria, TB, cancer and more): A theory of Impact or Protected Complement (IPC) immunity
Tom H. Jin, DTI Biologics, USA
12:35-13:00

Lunch & Networking | @ Syrah Restaurant

12:35-13:00

09:30-10:05

Constantinos Petrovas, Vaccine Research Center, NIAID, NIH, USA
14:50-15:15

New Novavax Vaccine candidates
Laura Hong, Vaccine Bioprocess & Bioanalytical Research, USA
15:15-15:40

Jean Boyer, Inovio Pharmaceuticals, USA
15:40-16:05

Emeline Ragonnaud, University of Copenhagen, Denmark
16:05-16:30

Therapeutic Vaccination & Clinical Trials & Technologies, Bioprocessing & Manufacturing

Chair: Abraham Bonnici, Vaxxcel Group, Switzerland

Formulation approaches to vaccine development
S. Fernando, Asta,Vaxxcel Canada, Canada
11:45-12:10

High therapeutic efficacy of a new cancer vaccine against the tumor associated antigen survivin
Ahmed Bouzidi, Vaxxcel Group, Switzerland
12:10-12:35

System and standard immunology demonstrated a prophylactic intradermal delivery of INO-4201 drives robust Ebola glycoprotein specific humoral and cellular immune responses in healthy volunteers in an open label phase I trial
Jean Boyes, Inovio Pharmaceuticals, USA
14:00-14:20

Imaging of genetic center immune dynamics: Applications in vaccine development
Corina Stefanescu-Vitvitska, Vaccine Research Center, NIAID, NIH, USA
14:25-14:50

Therapeutic vaccine against primate papillomavirus infections of the cervix
Laura Tran, Vaccine Research & Development Research, USA
15:15-15:40

Cell immune therapy of cancers using anti - gene anti IGF-I vaccine
Jermaine Tran, UVA, University, USA
16:05-16:30

BPZ11, a live attenuated herpesvirus vaccine Manufacturing challenges & solutions
Marcel Traxel, Bad Biosciences, Belgium
16:40-16:50

The role of positive influence of Venom Immunotherapy (VIT) on other allergies
Leonora Nienke Everts, Abagelhome immunology, Russia
16:55-17:20

13:00-14:00

11:20-11:45

09:40-10:05

08:30-08:25

08:25-08:50

08:50-09:15

09:15-09:40

09:40-10:05

10:05-10:30

10:30-10:55

10:55-11:20

11:20-11:45

11:45-12:10

12:10-12:35

12:35-13:00

13:00-14:00